Allogene says Phase 1 trial shows 31% response rate for ALLO-316 in CD70-high metastatic kidney cancer

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc.

ALLO

0.00
  • Allogene Therapeutics disclosed Journal of Clinical Oncology publication of Phase 1 TRAVERSE results for ALLO-316 in metastatic renal cell carcinoma.
  • Recommended Phase 2 regimen delivered a 25% confirmed response rate; 31% in tumors with CD70 TPS ≥50%.
  • Responses lasted 8 to 18+ months; median duration of response not reached.
  • Safety profile described as manageable; no Grade 5 adverse events in Phase 1b.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150830PRIMZONEFULLFEED9762499) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.